Last reviewed · How we verify
NCT06236698
The Diagnostic Performance of 24-hour Urinary Aldosterone for Primary Aldosteronism
trial testing 24-hour urinary aldosterone measurement in Primary Aldosteronism in 999 participants. Completed in 30 October 2024.
30 March 2024
Quick facts
| Lead sponsor | Zhiming Zhu |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 999 |
| Start date | 1 March 2022 |
| Primary completion | 30 March 2024 |
| Estimated completion | 30 October 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- 24-hour urinary aldosterone measurement
Conditions studied
- Primary Aldosteronism — all drugs for Primary Aldosteronism →
- Hypertension — all drugs for Hypertension →
Sponsor
Zhiming Zhu — full company profile →
Who can join
Adults 18 to 80, any sex, with Primary Aldosteronism or Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an observational study to define the cut-off value of 24-hour urinary aldosterone for diagnosing primary aldosteronism in hypertensive patients in our center. Plasma aldosterone and renin measurements are subject to significant intra-individual variability, including variation related to posture, time of day and sodium balance. Aldosterone secretion is not constant and may be subject to diurnal variation. As such one-off testing of ARR, does not consider the salt status of the individual necessitating repetition of tests to ensure false negative or false positive test results are ruled out. The value of accumulated aldosterone in a 24-hour sample has the advantage that it does not depend on circadian variation. This study will help establish the positivity rates of 24-hour urine aldosterone, and test the robustness of current standard guidelines for primary aldosteronism screening and case confirmation. Previous studies reported that primary aldosteronism is associated with a higher risk of CV complications and a higher prevalence of target organ damage. Also, previous studies reported on the association of echocardiographic parameters with circulating or urinary aldosterone. Therefore, we intent to investigate the independent associations of different target organ damage with the urinary excretion of aldosterone.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06236698
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Primary Aldosteronism
Currently open trials in the same condition.
- NCT07298954 — Sequential Combined Versus Single-Strategy Adrenal Venous Sampling for Primary Aldosteronism(SCOPE) · NA · recruiting
- NCT07111351 — Multi-omics Studies of Primary Aldosteronism · recruiting
- NCT07027254 — PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism · NA · recruiting
- NCT06941116 — Steroids-Based Screening for Primary Aldosteronism · recruiting
- NCT06955286 — Study on the Incidence of Adrenal Insufficiency After Surgery in Primary Aldosteronism Patients Concurrent With or Witho · recruiting
Other Zhiming Zhu trials
Trials by the same sponsor.
- NCT05068895 — Assessment of Metabolic Profiles of Lower Extremity Arterial Disease in Patiens Withe Type 2 Diabetes · unknown
- NCT01408446 — Effects and Safety of Menthol on Blood Pressure and Metabolic Parameters in Prehypertensive and Mild Hypertensive Patien · Phase 2, PHASE3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06236698 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhiming Zhu
- Last refreshed: 16 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06236698.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing